Fig. 2From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerSummary of best overall response by RECIST criteria. Abbreviations: PR, partial response; SD, stable disease; PD, progressive diseaseBack to article page